Literature DB >> 11100378

Expression patterns of the E-cadherin-catenin cell-cell adhesion complex in gastric cancer.

G Karatzas1, A J Karayiannakis, K N Syrigos, E Chatzigianni, S Papanikolaou, G Simatos, D Papanikolaou, S Bogris.   

Abstract

BACKGROUND/AIMS: The E-cadherin-catenin complex plays a key role in intercellular adhesion of epithelial cells. Aberrant expression and/or function of its components have been implicated in tumor progression and metastasis. We evaluated the expression of the E-cadherin-catenin complex in gastric cancer by immunohistochemistry and investigated its relationship to histopathological features.
METHODOLOGY: The expression of E-cadherin, alpha-, beta-, and gamma-catenin, and p120 protein was evaluated by immunohistochemistry in 36 formalin-fixed, paraffin-embedded specimens of gastric cancer.
RESULTS: In benign gastric mucosa all five molecules co-localized at the cell membrane. Reduced E-cadherin, alpha-, beta-, and gamma-catenin, and p120 expression was found in 67%, 61%, 50%, 64%, and 56% of cases, respectively. The expression of E-cadherin and beta-catenin correlated significantly with the histological type and the degree of tumor differentiation. gamma-Catenin expression correlated only with the histological type of the tumor. The expression of E-cadherin correlated significantly with alpha-, beta- and gamma-catenin, and p120 expression, respectively. The expression of E-cadherin and alpha-catenin showed the highest concordance.
CONCLUSIONS: In gastric cancer, reduced E-cadherin, catenin and p120 expressions are related events with E-cadherin showing the most frequent aberrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11100378

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42.

Authors:  Emhonta Johnson; Darcie D Seachrist; Carlos M DeLeon-Rodriguez; Kristen L Lozada; John Miedler; Fadi W Abdul-Karim; Ruth A Keri
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

Review 2.  Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis.

Authors:  Li-Fu Li; Zheng-Jie Wei; Hong Sun; Bo Jiang
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

3.  Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival.

Authors:  Yong-Ning Zhou; Cai-Pu Xu; Biao Han; Min Li; Liang Qiao; Dian-Chun Fang; Jian-Min Yang
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

4.  A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.

Authors:  Helen J Mackay; Heather J Au; Elaine McWhirter; Thierry Alcindor; Andrea Jarvi; Katrina MacAlpine; Lisa Wang; John J Wright; Amit M Oza
Journal:  Invest New Drugs       Date:  2011-03-12       Impact factor: 3.850

5.  Alpha-catenin expression is decreased in patients with gastric carcinoma.

Authors:  Yong-Ning Zhou; Cai-Pu Xu; Yu Chen; Biao Han; Shi-Ming Yang; Dian-Chun Fang
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

6.  Relationship between beta-catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia.

Authors:  Adriana Romiti; Angelo Zullo; Francesco Borrini; Ida Sarcina; Cesare Hassan; Simon Winn; Silverio Tomao; Aldo Vecchione; Sergio Morini; Pietro Mingazzini
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

7.  PPARgamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations.

Authors:  Ying Jiang; Lin Zou; Chunhui Zhang; Song He; Chun Cheng; Junfei Xu; Weiqi Lu; Yong Zhang; Hua Zhang; Donglin Wang; Aiguo Shen
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-03       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.